ArticleCancer cell2016
Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities.
Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- BRD9 at the crossroads of splicing, chromatin remodeling, and hematopoiesis.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2026Review
- Humanized mouse models in MDS.Cell death & disease · 2025Review
- In-depth functional analysis of BRD9 in fetal hematopoiesis reveals context-dependent roles.iScience · 2025Article
- Low-risk MDS-A spotlight on precision medicine forHemaSphere · 2025Review
- Roles and mechanisms of aberrant alternative splicing in melanoma - implications for targeted therapy and immunotherapy resistance.Cancer cell international · 2024Review
- Dysregulated minor intron splicing in cancer.Cancer science · 2022Review
- Article
- Article
- Differential RNA splicing as a potentially important driver mechanism in multiple myeloma.Haematologica · 2021Article
- Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia.Cancer discovery · 2020Article
- Roles and mechanisms of alternative splicing in cancer - implications for care.Nature reviews. Clinical oncology · 2020Review
- The biological function and clinical significance of SF3B1 mutations in cancer.Biomarker research · 2020Review
- Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.Genes, chromosomes & cancer · 2019Review
- Review
- Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.Journal of clinical and experimental hematopathology : JCEH · 2019Article
- A cell-based splicing reporter system to identify regulators of cis-splicing between adjacent genes.Nucleic acids research · 2019Article
- Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.Oncotarget · 2019Article
- RNA Splicing and Disease: Animal Models to Therapies.Trends in genetics : TIG · 2019Review
- Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor geneProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In this issue of Cancer Cell, Obeng et al. identify the consequences of expressing the most common mutation in the spliceosomal gene SF3B1 on hematopoiesis. The knockin mouse model described represents a valuable tool to dissect the effects of SF3B1 mutations on transformation, splicing, and less well-characterized functions of SF3B1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.